二甲双胍对乳腺癌合并2型糖尿病患者癌组织Caspase-3、Caspase-9表达的影响

目的 观察二甲双胍对乳腺癌合并2型糖尿病患者癌组织中半胱天冬氨酸蛋白酶-3（Caspase-3）及Caspase-9表达的影响.方法 选择乳腺癌合并2型糖尿病112例,其中应用二甲双胍治疗者43例（二甲双胍组）、未用二甲双胍治疗者69例（糖癌组）,单纯乳腺癌112例（单纯癌症组）,采用免疫组化SP法检测癌组织中的Caspase-3、Caspase-9.结果 二甲双胍组癌组织中Caspase-3、Caspase-9表达量分别为138.24±8.68、140.21±6.34,糖癌组分别为153.43±5.59、156.17±8.25,单纯癌症组分别为112.70±4.28、121.43±6.67;三组两两比较,P均＜0.05.结论 二甲双胍可降低乳腺癌合并2型糖尿病患者癌组织中Caspase-3及Caspase-9表达,这可能是其抑制乳腺癌发展的作用机制.

Effects of metformin on expression of Caspase-3 and Caspase-9 in with breast carcinoma type 2 diabetic patients

Objective To observe the effects of metformin on the expression of Caspase -3 and Ccaspase-9 in breast carcinoma with type 2 diabetic patients with breast carcinoma. Methods The expression of caspase-3 and Caspase-9 in 43 breast cancer with type 2 diabetic patients treated with metformin （ metformin group） , 69 cases of patients without the use of metformin （sugar cancer group） and 112 cases of patients with breast cancer （simple cancer group） was detected by the immunohistoehemical SP method. Results The expression levels of Caspase-3, Caspase-9 were seperately 138.24 ± 8.68, 140.21 ± 6.34 in the metformin group, 153.43 ± 5.59 and 156.17 ± 8.25 in the sugar cancer group, and 112.70 ± 4.28, 121.43 ± 6.67 in the pure cancer group. There were statistical differences between each two groups （ all P 〈 0.05 ）. Con- clusions Metformin can reduce the expression of Caspase-3 and Caspase-9 in breast carcinoma with type 2 diabetic pa- tients, which may be the mechanism of inhibition of breast cancer.